All Stories

  1. Synergistic effect of lactoferrin combined with fluconazole to overcome antifungal resistance in Candida species
  2. Aetiology of Vulvovaginal Candidiasis in Ecuador and In Vitro Antifungal Activity Against Candida Vaginal Isolates
  3. Aetiology of Vulvovaginal Candidiasis in Ecuador and In Vitro Antifungal Activity Against <em>Candida</em> Vaginal Isolates
  4. The future of non-invasive azole antifungal treatment options for the management of vulvovaginal candidiasis
  5. In Vitro Assessment of Fluconazole and Cyclosporine A Antifungal Activities: A Promising Drug Combination Against Different Candida Species
  6. Characterization of Yeast Isolated from the Gut Microbiota of Tunisian Children with Autism Spectrum Disorder
  7. Efficacy of the combination of amphotericin B and echinocandins against Candida auris in vitro and in the Caenorhabditis elegans host model
  8. In Vitro and In Vivo Activity of Citral in Combination with Amphotericin B, Anidulafungin and Fluconazole against Candida auris Isolates
  9. Presence and implication of Candida spp. in patients with peri‐implantitis enrolled in a supportive peri‐implant therapy program of the Basque Country (Spain). A case–control study
  10. PK / PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris
  11. Assessing pH‐dependent activities of virulence factors secreted by Candida albicans
  12. Antimicrobial Peptides with Anti-Candida Activity
  13. Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?
  14. In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
  15. In vitro and in vivo anti-Candida activity of citral in combination with fluconazole
  16. Candidiasis by Candida glabrata, Candida nivariensis and Candida bracarensis in Galleria mellonella: Virulence and Therapeutic Responses to Echinocandins
  17. In vitro activities of carvacrol, cinnamaldehyde and thymol against Candida biofilms
  18. In Vitro Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Amphotericin B against Candida auris
  19. In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris
  20. A systematic review on the implication of Candida in peri-implantitis
  21. Erratum for Miranda-Cadena et al., “Development and Characterization of Monoolein-Based Liposomes of Carvacrol, Cinnamaldehyde, Citral, or Thymol with Anti- Candida Activities”
  22. Anfotericina B liposomal: treinta años de una herramienta muy eficaz para el tratamiento de las micosis invasoras
  23. In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris
  24. Development and Characterization of Monoolein-Based Liposomes of Carvacrol, Cinnamaldehyde, Citral, or Thymol with Anti- Candida Activities
  25. Candida parapsilosis Colony Morphotype Forecasts Biofilm Formation of Clinical Isolates
  26. Virulence of Candida auris from different clinical origins in Caenorhabditis elegans and Galleria mellonella host models
  27. Candida duobushaemulonii: An Old But Unreported Pathogen
  28. Caenorhabditis elegans as a Model System To Assess Candida glabrata, Candida nivariensis , and Candida bracarensis Virulence and Antifungal Efficacy
  29. Fungal co-infection in COVID-19 patients: Should we be concerned?
  30. Synthesis, Physical, Mechanical and Antibacterial Properties of Nanocomposites Based on Poly(vinyl alcohol)/Graphene Oxide–Silver Nanoparticles
  31. Utility of two PCR‐RFLP‐based techniques for identification of Candida parapsilosis complex blood isolates
  32. Graphene Oxide–Silver Nanoparticle Nanohybrids: Synthesis, Characterization, and Antimicrobial Properties
  33. Candida albicans biofilms on different materials for manufacturing implant abutments and prostheses
  34. Disinfectant Activity of A Portable Ultraviolet C Equipment
  35. Role of Porphyromonas gingivalis in oral squamous cell carcinoma development: A systematic review
  36. One-step eco-friendly synthesized silver-graphene oxide/poly(vinyl alcohol) antibacterial nanocomposites
  37. Effect of biomaterials hydrophobicity and roughness on biofilm development
  38. Corrigendum: Antifungal Activity of the Human Uterine Cervical Stem Cells Conditioned Medium (hUCESC-CM) Against Candida albicans and Other Medically Relevant Species of Candida
  39. Killing kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activity
  40. Therapeutic tools for oral candidiasis: Current and new antifungal drugs
  41. Antifungal Activity of the Human Uterine Cervical Stem Cells Conditioned Medium (hUCESC-CM) Against Candida albicans and Other Medically Relevant Species of Candida
  42. Epidemiología de las micosis invasoras: un paisaje en continuo cambio
  43. Prevalence and antifungal susceptibility profiles of Candida glabrata, Candida parapsilosis and their close-related species in oral candidiasis
  44. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods
  45. Design and validation of a multiplex PCR protocol for microsatellite typing of Candida parapsilosis sensu stricto isolates
  46. The continuous changes in the aetiology and epidemiology of invasive candidiasis: from familiar Candida albicans to multiresistant Candida auris
  47. Oral Candida colonization in patients with chronic periodontitis. Is there any relationship?
  48. Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis
  49. Declaración a favor de la creación de la Asociación Iberoamericana de Micología Médica
  50. Editorial: EHUDW01, First EHU-DELFIN Program Workshop, Bilbao, Jul, 201
  51. Comparative Study of Invasive Candidiasis in Mexico and Spain
  52. Phytochemical composition, anti-biofilm and anti-quorum sensing potential of fruit, stem and leaves of Salvadora persica L. methanolic extracts
  53. EPICO 4.0. ‘Total quality’ in the management of invasive candidiasis in critically ill patients by analysing the integrated process
  54. Usefulness of the Non-conventional Caenorhabditis elegans Model to Assess Candida Virulence
  55. Vancomycin heteroresistant community associated methicillin-resistant Staphylococcus aureus ST72-SCCmecIVa strain colonizing the nostrils of a five-year-old Spanish girl
  56. Vancomycin heteroresistant community associated methicillin-resistant Staphylococcus aureus ST72-SCCmecIVa strain colonizing the nostrils of a five-year-old Spanish girl
  57. In Vitro Antifungal Susceptibility of Oral Candida Isolates from Patients Suffering from Caries and Chronic Periodontitis
  58. Detection and characterization of surface microbial contamination in emergency ambulances
  59. Erratum to: “EPICO 3.0. Management of non-neutropenic patients in medical wards” [Rev Iberoam Micol. 33 (4) (2016) 216–223]
  60. Impact of a multifaceted educational intervention including serious games to improve the management of invasive candidiasis in critically ill patients
  61. Twitter as a Tool for Teaching and Communicating Microbiology: The #microMOOCSEM Initiative †
  62. Postantifungal effect of caspofungin against the Candida albicans and Candida parapsilosis clades
  63. EPICO 3.0. Management of non-neutropenic patients in medical wards
  64. Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?
  65. Enfermedad fúngica invasiva por Candida y otros hongos levaduriformes
  66. Aspectos actuales de las enfermedades invasoras causadas por Candida y otros hongos levaduriformes
  67. In vitro pharmacodynamic modelling of anidulafungin against Candida spp.
  68. Caries andCandidacolonisation in adult patients in Basque Country (Spain)
  69. Risk Groups for Acquiring Fungal Infections
  70. Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method
  71. Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis
  72. Comparison of the in vitro activity of echinocandins against Candida albicans , Candida dubliniensis , and Candida africana by time–kill curves
  73. In VitroFungicidal Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis Evaluated by Time-Kill Studies
  74. Enfermedad fúngica invasiva por hongos filamentosos
  75. Aspectos actuales de las enfermedades invasivas por hongos filamentosos
  76. EPICO 2.0 project. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations
  77. Candidaantigens and immune responses: implications for a vaccine
  78. Epidemiology of candidaemia and invasive candidiasis. A changing face
  79. State of the Art in the Laboratory Methods for the Diagnosis of Invasive Fungal Diseases
  80. List of Contributors
  81. Presencia de Candida en la estomatitis aftosa recidivante
  82. Épico project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients
  83. Proyecto Épico: formulación de unas recomendaciones educativas con metodología DELPHI para pacientes adultos críticos no neutropénicos y con candidiasis invasiva
  84. Épico project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients
  85. Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis
  86. Enfermedad fúngica invasora: ¿Diagnóstico micológico convencional o molecular?
  87. Accurate Identification of Candida parapsilosis (Sensu Lato) by Use of Mitochondrial DNA and Real-Time PCR
  88. Validation of the PCR–dHPLC method for rapid identification of Candida glabrata phylogenetically related species in different biological matrices
  89. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey
  90. Periodontopathogen and Epstein-Barr Virus Contamination Affects Transplanted Bone Volume in Sinus Augmentation
  91. In vitro activities of natural products against oral Candida isolates from denture wearers
  92. Variation in biofilm formation among blood and oral isolates of Candida albicans and Candida dubliniensis
  93. Prospective Multicenter Study of the Epidemiology, Molecular Identification, and Antifungal Susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Isolated from Patients with Candidemia
  94. Anidulafungin in Treatment of Experimental Invasive Infection by Candida parapsilosis:In VitroActivity, (1→3)-β-d-Glucan and Mannan Serum Levels, Histopathological Findings, andIn VivoEfficacy
  95. In Vitro Activities of New Triazole Antifungal Agents, Posaconazole and Voriconazole, Against Oral Candida Isolates from Patients Suffering from Denture Stomatitis
  96. Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital
  97. Enfermedades fúngicas invasoras en receptores de trasplante de órgano sólido
  98. Candidiasis, aspergilosis y otras micosis invasoras en receptores de trasplantes de órgano sólido
  99. Recomendaciones sobre el tratamiento de la enfermedad fúngica invasiva por Aspergillus spp. y otros hongos filamentosos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011
  100. Fungicidal Monoclonal Antibody C7 Interferes with Iron Acquisition in Candida albicans
  101. Saccharomyces cerevisiae Vaginitis: Microbiology and In Vitro Antifungal Susceptibility
  102. Clinical factors associated with a Candida albicansGerm Tube Antibody positive test in Intensive Care Unit patients
  103. Evidencias científicas que respaldan el uso de micafungina en el tratamiento de la candidiasis invasora
  104. Posaconazole susceptibility of clinical yeast isolates determined by an agar diffusion and microdilution method
  105. In memoriam a José Pontón
  106. Recomendaciones sobre el diagnóstico de la enfermedad fúngica invasora de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2010
  107. Evaluation of the VITEK 2 system to test the susceptibility ofCandidaspp.,Trichosporon asahiiandCryptococcus neoformansto amphotericin B, flucytosine, fluconazole and voriconazole: a comparison with the M27-A3 reference method
  108. In vitroactivity of voriconazole against Mexican oral yeast isolates
  109. Candidemias y candidiasis invasivas nosocomiales
  110. Phospholipase and proteinase activities of Candida isolates from denture wearers
  111. Paradoxical Growth of Candida dubliniensis Does Not Preclude In Vivo Response to Echinocandin Therapy
  112. Kinetic Patterns of Candida albicans Germ Tube Antibody in Critically Ill Patients: Influence on Mortality
  113. Evaluation of CHROM-Pal medium for the isolation and direct identification of Candida dubliniensis in primary cultures from the oral cavity
  114. La Revista Iberoamericana de Micología se debe adaptar a los tiempos actuales
  115. Confundiendo al confuso: reflexiones sobre el factor de impacto, el índice h(irsch), el valor Q y otros cofactores que influyen en la felicidad del investigador
  116. Clinical significance of the detection of Candida albicans germ tube-specific antibodies in critically ill patients
  117. Evaluation of two commercialized systems for the rapid identification of medically important yeasts
  118. Transient fungaemia due to Candida, pelliculosa in a patient with AIDS
  119. Evaluation of the Albicans IDR plate method for the rapid identification of Candida albicans
  120. Actividad antifúngica in vitro de la micafungina
  121. Actividad de la micafungina contra las biopelículas de Candida
  122. Micafungina, una nueva candina para el tratamiento de las micosis invasoras
  123. Isolation of Candida dubliniensis in denture stomatitis
  124. Enteric Fever-Like Syndrome Caused by Raoultella ornithinolytica (Klebsiella ornithinolytica)
  125. In VitroAntifungal Activity of Sertaconazole Nitrate Against Recent Isolates of Onychomycosis Causative Agents
  126. Anidulafungina en la infección fúngica invasora: perspectivas actuales
  127. Actividad antifúngica in vitro de la anidulafungina
  128. Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis
  129. Latest developments in fungal lung infection in solid organ transplantation (SOT)
  130. En la primera vuelta de la segunda escalera me volví y contemplé: 25 años de Revista Iberoamericana de Micología
  131. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre
  132. Evaluación comparativa de ATB Fungus 2 y Sensititre YeastOne en el estudio de la sensibilidad in vitro de Candida a los antifúngicos
  133. In Vitro Interactions of Micafungin with Amphotericin B against Clinical Isolates of Candida spp.
  134. Isolation ofCandida africana, probable atypical strains ofCandida albicans, from a patient with vaginitis
  135. Activity of Caspofungin and Voriconazole against Clinical Isolates of Candida and Other Medically Important Yeasts by the CLSI M-44A Disk Diffusion Method with Neo-Sensitabs Tablets
  136. Actividad in vitro de la anfotericina B y la anidulafungina sobre biopelículas de Candida albicans y Candida tropicalis
  137. Identificación rápida de Candida dubliniensis mediante la prueba Bichro-Dubli®
  138. In vitro activity of micafungin combined with itraconazole against Candida spp.
  139. Presente y futuro de voriconazol en el tratamiento de las micosis invasoras: el inseparable binomio diagnóstico-tratamiento
  140. Actividad antifúngica in vitro de voriconazol: Nuevos datos después de los primeros años de experiencia clínica
  141. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis
  142. Comparación de un método de amplificación aleatoria del ADN polimorfo (RAPD) y el sistema ATB ID32C para la identificación de aislamientos clínicos de Candida
  143. In vitro interaction of micafungin and fluconazole against Candida
  144. Comparison of Tablet and Disk Diffusion Methods for Fluconazole and VoriconazoleIn VitroActivity Testing Against Clinical Yeast Isolates
  145. La valiosa incorporación del nuevo Director ejecutivo, Josep Guarro i Artigas
  146. Biofilm development by clinical isolates ofMalassezia pachydermatis
  147. Update on invasive fungal infections: the last two years
  148. New microbiological techniques for the diagnosis of invasive mycoses caused by filamentous fungi
  149. Utilidad de la detección de (1→3)-ß-D-glucano y anticuerpos anti-micelio de Candida albicans para el diagnóstico y seguimiento terapéutico de la candidiasis invasora en pacientes neutropénicos adultos
  150. Aislamiento de Issatchenkia occidentalis en el esófago de un paciente con leucemia
  151. In Vitro Activities of Voriconazole and Five Licensed Antifungal Agents Against Candida dubliniensis: Comparison of CLSI M27-A2, Sensititre YeastOne, Disk Diffusion, and Etest Methods
  152. Evaluation of the New Chromogenic Medium Candida ID 2 for Isolation and Identification of Candida albicans and Other Medically Important Candida Species
  153. In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast OneTM
  154. Evaluation of Bichro-Dubli Fumouze® to distinguish Candida dubliniensis from Candida albicans
  155. Anticuerpos anti-micelio de Candida albicans en dos pacientes de cuidados intensivos con candidiasis invasora
  156. Mecanismos de resistencia a la terapéutica antifúngica
  157. Usefulness of Candida ID2 agar for the presumptive identification ofCandida dubliniensis
  158. Introduction to the special issue of the Revista Iberoamericana de Micología devoted to Fungal Genomes
  159. Supplementation of CHROMagar Candida Medium with Pal's Medium for Rapid Identification of Candida dubliniensis
  160. Oral Candida Isolates Colonizing or Infecting Human Immunodeficiency Virus-Infected and Healthy Persons in Mexico
  161. Sertaconazole: updated review of a topical antifungal agent
  162. Actividad antifúngica in vitro de voriconazol contra dermatofitos y aislamientos superficiales de Scopulariopsis brevicaulis
  163. Prevalencia, microbiología y patrones de sensibilidad a los antifúngicos de los aislamientos orales de Candida que colonizaban o infectaban a pacientes mexicanos con infección por VIH o sida y a personas sanas
  164. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections
  165. Current Developments in Anti-Fungal Agents
  166. Evaluation of API ID 32C® and VITEK-2® to identify Candida dubliniensis
  167. Antifungal Activity of Amphotericin B and Itraconazole against Filamentous Fungi: Comparison of the Sensititre Yeast OneŴ and NCCLS M38-A Reference Methods
  168. Evaluación de una nueva técnica comercializada (Candida albicans IFA IgG) para el diagnóstico de la candidiasis invasiva
  169. In vitro Antifungal Activity of Sertaconazole Compared with Nine Other Drugs against 250 Clinical Isolates of Dermatophytes and Scopulariopsis brevicaulis
  170. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans
  171. Performance of BacticardTM Candida compared with the germ tube test for the presumptive identification of Candida albicans
  172. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species
  173. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method
  174. Ciclopiroxolamine: in vitro antifungal activity against clinical yeast isolates
  175. Candida dubliniensis, a new fungal pathogen
  176. Comparison of in vitro Antifungal Activities of Amphotericin B Lipid Complex with Itraconazole against 708 Clinical Yeast Isolates and Opportunistic Moulds Determined by National Committee for Clinical Laboratory Standards Methods M27-A and M38-P
  177. Comparison of the Sensititre YeastOne Colorimetric Microdilution Panel and the NCCLS Broth Microdilution Method for Antifungal Susceptibility Testing against Candida Species
  178. Serological Differentiation of Experimentally Induced Candida dubliniensis and Candida albicans Infections
  179. Comparative evaluation of three commercial software packages for analysis of DNA polymorphism patterns
  180. S2.5 Nuevas perspectivas en la terapia antifúngica
  181. Sertaconazole:In-VitroAntifungal Activity Against Vaginal and Other Superficial Yeast Isolates
  182. In Vitro Activity of a New Liposomal Nystatin Formulation Against Opportunistic Fungal Pathogens
  183. Effect of salivary secretory IgA on the adhesion of Candida albicans to polystyrene
  184. Influence of Environmental pH on the Reactivity of Candida albicans with Salivary IgA
  185. Comparative in vitro Antifungal Activity of Amphotericin B Lipid Complex, Amphotericin B and Fluconazole
  186. In vitro Susceptibility of Candida dubliniensis to Current and New Antifungal Agents
  187. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients
  188. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole
  189. A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp.
  190. Comparison of morphotypic and genotypic methods for strain delineation inCandida
  191. Reactivity of Candida albicans Germ Tubes with Salivary Secretory IgA
  192. Utility of albicans ID plate for rapid identification of Candida albicans in clinical samples
  193. Effect of monoclonal antibodies directed against Candida albicans cell wall antigens on the adhesion of the fungus to polystyrene
  194. Cytological changes in oral mucosa in denture stomatitis
  195. Candida biotypes in patients with oral leukoplakia and lichen planus
  196. Evaluation of a commercial medium for identification ofCandida species
  197. A new method of antibiotyping yeasts for subspecies discrimination and distribution in human clinical specimens
  198. Variability in expression of antigens responsible for serotype specificity in Candida albicans
  199. Biotype Diversity of Candida parapsilosis and Its Relationship to the Clinical Source and Experimental Pathogenicity
  200. Use of DNA fingerprinting and biotyping methods to study a Candida albicans outbreak in a neonatal intensive care unit
  201. Fatal Candida famata Peritonitis in a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis Who Was Treated with Fluconazole
  202. Prevalence of Candida parapsilosis in the Oral Cavities of Infants in Spain
  203. Multicenter Evaluation of ATB Fungus: A Standardized Micromethod for Yeast Susceptibility Testing
  204. Detection of Anti-CandidaalbcansIgE Antibodies in Vaginal Washes from Patients with Acute Vulvovaginal Candidiasis
  205. Fatal Disseminated Infection by Scedosporium inflatum after Bone Marrow Transplantation
  206. Identification of antigens reacting with anti-Candida albicans germ tube antibodies
  207. Vulvovaginal candidiasis refractory to treatment with fluconazole
  208. Candidal infection of bone: Assessment of serologic tests in diagnosis and management
  209. In vitro susceptibility ofAeromonas caviae, Aeromonas hydrophila andAeromonas sobria to fifteen antibacterial agents
  210. Value of detection of antibodies toCandida albicans germ tube in the diagnosis of systemic candidosis
  211. Determination of monosaccharides by high-performance liquid chromatography in systemic candidosis
  212. Vulvovaginal Candidiasis: pathogenesis and diagnosis
  213. Antibodies against Trichosporon beigelii in vaginal washings from asymptomatic women
  214. Isolation of dysgonic strains ofMicrosporum canisin Bilbao (Spain)
  215. Detection of antibodies toCandida albicans germ tube in the diagnosis of systemic candidiasis
  216. Cellular and humoral immune responses to Candida albicans in subcutaneously infected mice
  217. Typing Fungal Isolates: Molecular Methods and Computerized Analysis
  218. Trichosporon, Magnusiomyces, and Geotrichum